Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. Its natural cleavage product GLP-1 (9-36), used to be considered a "bio-inactive" metabolite mainly because of its lack of insulinotropic effects and low affinity for GLP-1 receptors, possesses unique properties such as anti-oxidant and cardiovascular protection. Little is known about the role of GLP-1 (9-36) in central nervous system.
| I N TR ODU C TI ON
Incretins refer to a group of metabolic hormones that stimulate a decrease in blood glucose levels. Glucagon-like peptide-1 (GLP-1) is a primary incretin hormone synthesized and released from gastrointestinal endocrine cells in response to meal ingestion and plays a crucial role in glucosestimulated insulin secretion (Campbell & Drucker, 2013) . Further, GLP-1 receptor (GLP-1R) is found throughout the central nervous system (CNS) and GLP-1 signaling is indicated in regulation of a variety of CNS functions including satiety, reward, neuroprotection, and stress (Baggio & Drucker, 2007; Poudyal, 2016) . Notably, GLP-1 and GLP-1R are expressed in the hippocampus, a brain structure known for its plasticity and is critical for learning and memory (Alvarez, Roncero, Chowen, Thorens, & Bl azquez, 1996; Merchenthaler, Lane, & Shughrue, 1999) . In agreement, administration of GLP-1 centrally (intracerebroventricular injection) in rats improves performance in learning and memory tasks that are dependent on integral hippocampal function (During et al., 2003) .
The native, major form of GLP-1 in humans is the amide, which is unstable (half-life <2 min) and rapidly cleaved by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-4) into GLP-1(9-36)amide ) hereafter], the major circulating metabolite of GLP-1 (7-36) (Baggio & Drucker, 2007; Deacon, Johnsen, & Holst, 1995; Hansen, Deacon, Ørskov, & Holst, 1999; Knudsen & Pridal, 1996) . Mainly because of its lack of insulinotropic activity and low affinity for the GLP-1R, GLP-1 (9-36) had been considered as a "bioinactive" metabolite of the "bioactive" GLP-1(7-36) (Knudsen & Pridal, 1996; Meier et al., 2006; Rolin , Deacon, Carr, & Ahr en, 2004; Sandoval & D'Alessio, 2015) . However, accumulating evidence has shown that GLP-1 (9-36) possesses important biological functions through mechanisms distinct from its precursor GLP-1(7-36) (Poudyal, 2016) . For instance, multiple lines of evidence demonstrate that GLP-1(9-36) exerts beneficial cardiovascular effects including protection from experimental animal models of cardiac infarction/ischemia and dilated cardiomyopathy. Whether these cardioprotective effects are dependent on GLP-1R remains elusive (Ban et al., 2008; Nikolaidis, Elahi, Shen, & Shannon, 2005; Poudyal, 2016; Robinson et al., 2016) . Further, GLP-1(9-36) alleviates and normalizes production of reactive oxygen species (ROS) associated with a model of hyperglycemia in human aortic endothelia cells (Giacco et al., 2015) .
Compared to cardiovascular systems, little is known about the effects of GLP-1(9-36) in the CNS. We recently reported that GLP-1(9-36) is able to rescue synaptic plasticity impairments and memory deficits displayed in an aged mouse model of Alzheimer's disease (AD), in correlation with the effects of decreasing mitochondria-derived ROS (Ma, Tzavaras, Tsokas, Landau, & Blitzer, 2012) . Meanwhile, the role of GLP-1 (9-36) in CNS under physiological conditions remains unclear, and whether GLP-1R mediates CNS effects of GLP-1 (9-36) is unknown. Herein, we aimed to investigate whether systematic treatment of GLP-1 (9-36) in young adult mice affects hippocampal synaptic plasticity, learning memory, and if so, what molecular mechanisms might be involved.
| M A TE RI A L S A ND M E TH ODS

| Mice
Breeders for C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME USA). All mice were housed in the Transgenic Mouse Facility at Wake Forest School of Medicine Animal Facility. Mice were kept in compliance with the National Institute of Health (NIH) guide for Care and Use of Laboratory Animals. The facility kept a 12 hr light/dark cycle with regular feeding, cage cleaning, and 24 hr access to water. Male and female mice, aged 3-5 months, were used for these experiments.
| Drug treatment
GLP-1(9-36) peptide (Eurogentec, Belgium) was administered daily via intraperitoneal injection (i.p.) at a dose of 500 ng/g/day beginning two weeks prior to behavioral testing and continued until mice were sacrificed for electrophysiology or biochemical assays. amide [EX(9-39)] (Tocris, UK) was administered daily via i.p. injection at a dose of 84.25 ng/g/day (Green et al., 2005) . For in vitro experiments, 100 pM of GLP-1 (9-36) was applied to hippocampal slices (Ma et al., 2012) . GLP-1 (9-36) was prepared as stock solution and was diluted to the final concentrations before use.
| Hippocampal slice preparation and electrophysiology
Acute 400 mm transverse hippocampal slices were prepared using a Leica VT1200S vibratome as described previously (Ma et al., 2014) . Slices were maintained before experimentation at room temperature for at least 2 hr in artificial cerebrospinal fluid containing (in mM) 118 NaCl, 3.5 KCl, 2.5 CaCl 2 , 1.3 MgSO 4 , 1.25 NaH 2 PO 4 , and 15 glucose, bubbled with 95% O 2 /5% CO 2 . For electrophysiology, monophasic, constant-current stimuli (100 ms) were delivered with a bipolar silver electrode placed in the stratum radiatum of area CA3. Field excitatory postsynaptic potentials (fEPSPs) were recorded using a glass microelectrode from the stratum radiatum of area CA1. Long-term potentiation (LTP) was induced using high-frequency stimulation (HFS) consisting of two 1-s 100 Hz trains separated by 60 s.
| Mouse behavioral testing
Morris water maze (MWM) test was performed as described (Ma et al., 2013) . The training paradigm for the hidden platform version of the MWM consists of four trials (60 s maximum; interval 15 min) each day for five consecutive days. The probe trial is carried out 2 hr after the completion of training on day 5. The visible platform task consists of four trials each day for two consecutive days with the escape platform marked by a visible cue and moves randomly between four locations. The trajectories are recorded with a video tracking system (Ethovision XT).
| Western blotting
Hippocampal slices were flash-frozen on dry ice and sonicated as previously described (Ma et al., 2013) . Samples containing equal amounts of protein lysate were loaded on 4-12% Tris-glycine SDS-PAGE gels for standard gel electrophoresis. Membranes were probed overnight at 4 8C using primary antibodies for the following antibodies: Kv4.2
(1:5,000; Alomone Labs); GluA1 (1:1,000; Cell Signaling); p-mTOR (Ser2448) (1:1,000; Cell Signaling); mTOR (1:1,000; Cell Signaling); pp70S6K (Thr389) (1:1,000; Cell Signaling); p70S6K (1:1,000; Cell Signaling); p-4EBP1(Thr37/46) (1:1,000; Cell Signaling); 4EBP1 (1:1,000; Cell Signaling); p-Akt (Ser473) (1:1,000; Cell Signaling); Akt (1:1,000; Cell Signaling); p-GSK3b (Ser9) (1:1,000; Cell Signaling); GSK3b (1:1,000; Cell Signaling); p-eIF2a (Ser51) (1:1,000; Cell Signaling); eIF2a (1:1,000; Cell Signaling); p-eEF2 (Thr56) (1:1,000; Cell Signaling); eEF2 (1:1,000; Cell Signaling); eEF1A (1:5,000; Millipore); p-AMPKa (Thr172) (1:1,000; Cell Signaling); AMPKa (1:1,000; Cell Signaling); GAPDH (1:10,000; Cell Signaling). Protein bands were visualized using chemiluminescence (Clarity TM ECL; Biorad) and the Biorad ChemiDoc TM MP imaging system. Densitometric analysis was performed using ImageJ. Data were normalized to GAPDH (for total proteins analysis) or relevant total proteins (for phospho proteins analysis) unless otherwise specified.
| SUnSET protein synthesis assay
SUnSET was performed as described (Ma et al., 2014) . Hippocampal slices were incubated with puromycin (1 lg/mL) for 60 min throughout were treated with 100 pM GLP-1 (9-36). At the end of drug treatment slices were harvested and frozen on dry ice; protein lysates were prepared for Western blotting. Puromycin-labeled proteins were identified using the mouse monoclonal antibody 12D10 (1:10,000; Millipore).
Protein synthesis levels were determined by taking total lane density in the molecular weight range of 10-250 kDa.
| Data analyses
Data were presented as mean 6 SEM. For comparison between two groups, a two-tailed independent Student's t test was used. For comparison between multiple groups ANOVA was used followed by individual post hoc tests when applicable. Error probabilities of p < 0.05
were considered statistically significant. ces from control mice with GLP-1 (9-36) (100 pM) followed by HFS and found that LTP was not altered, which is consistent with previous studies (Ma et al., 2012) . These findings indicate that chronic in vivo treatment of GLP-1 (9-36) enhances hippocampal long-term synaptic plasticity.
| Spatial learning and memory is not altered by GLP-1 (9-36) treatment
We previously reported that GLP-1 (9-36) treatment for two weeks is able to rescue cognitive impairments associated with an aged mouse model of AD (Ma et al., 2012) . To determine the effects of GLP-1 (9-36) on learning and memory under normal physiological conditions, wild type mice were treated with GLP-1 (9-36) (500 ng/g/day ip injection) for two weeks and tested with hidden platform MWM behavioral task to assess hippocampus-dependent spatial learning and memory. In short, GLP-1 (9- and memory including vision, motivation, and/or swimming ability, we tested the mice on the visible platform task and did not observe any significant differences between GLP-1 (9-36)-and saline-treated groups ( Figure 2d ). In addition, GLP-1 (9-36) had no effect on travel distance or velocity of mice during probe trial (Figure 2e,f) . Taken together, these data indicate that chronic GLP-1 (9-36) treatment for two weeks did not alter spatial learning and memory in young, adult mice.
3.3 | GLP-1 (9-36) administration in vivo results into decrease of Kv4.2 expression in hippocampus
Next, we sought to examine the molecular mechanisms potentially associated with the LTP-enhancing effects of GLP-1 (9-36) in vivo treatment. As noted, both early, (i.e. the induction phase of LTP) and late (i.e. the maintenance phase of LTP) LTP were significantly facilitated by GLP-1 (9-36) (Figure 1) . A key mechanism for LTP induction at hippocampal pyramidal neurons under physiological conditions involves regulation of Kv4.2, a voltage-gated potassium channel and a dominant player in controlling dendritic excitability of hippocampus (Chen et al., 2006; Hoffman, Magee, Colbert, & Johnston, 1997; Johnston et al., 2000) . In agreement, inhibition of Kv4.2 via pharmacological or genetic approaches causes increased dendritic membrane excitability and enhancement of LTP (Chen et al., 2006; Ramakers & Storm, 2002) .
By performing Western blotting on hippocampal tissue, we found that protein levels of Kv4.2 were significantly reduced in mice treated with GLP-1 (9-36), compared to the saline-treated group (Figure 3a) , which is consistent with the electrophysiology data showing early LTP facilitating effects. In comparison, acute in vitro treatment of hippocampal slices with GLP-1 (9-36) did not affect protein levels of Kv4.2 ( Figure   3b ). Moreover, we examined levels of GluA1 protein, an essential subunit of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, and did not find any difference between GLP-1 (9-36)-and saline-treated groups (Figure 3c ). Further, hippocampal slices 3.4 | GLP-1 (9-36) administration in vivo does not affect mTORC1 signaling cascade or eIF2a phosphorylation
A substantial body of evidence demonstrates that maintenance of long-lasting forms of synaptic plasticity is dependent on de novo protein synthesis (i.e. mRNA translation) (Alberini, 2008; Klann & Dever, 2004) . Given the enhancing effects of GLP-1 (9-36) on late phase LTP (Figure 1) , we went on to investigate whether GLP-1 (9-36) in vivo treatment influences molecular signaling pathways controlling protein synthesis. Protein synthesis includes three phases: initiation, elongation, and termination. Many studies support a link between regulation of translational initiation and synaptic plasticity (Klann, , Antion, Banko, & Hou ., 2004) The mammalian target of rapamycin complex 1 (mTORC1) is a central regulator of translation initiation and its role in memory and synaptic plasticity has been intensively studied (Hoeffer & Klann, 2010) . Surprisingly, we did not observe any effects of GLP-1 (9-36) on mTORC1 signaling, as indicated by no change in the levels of mTOR phosphorylation and activity (assessed by phosphorylation at the mTOR-dependent sites) of its two downstream substrates: p70S6K
and 4EBP1 (Figure 4a-c) . Consistently, GLP-1 (9-36) treatment did not affect activity (as assessed by phosphorylation levels) of Akt and GSK3b, two established upstream regulators of mTORC1 (Figure 4d ,e) (Ma et al., 2011) .
Another translational mechanism important for long-lasting forms of synaptic plasticity involves phosphorylation on a subunit of mRNA translational initiation factor 2 (eIF2a), which leads to suppression of general protein synthesis (Trinh & Klann, 2013; Wek, Jiang, & Anthony, 2006) . Nevertheless, we did not find any significant changes in hippocampal levels of phospho-eIF2a in GLP-1(9-36)-treated mice, relative to controls (Figure 4f ). Moreover, acute in vitro treatment of hippocampal slices with GLP-1 (9-36) did not show any effects on phosphorylation levels of either mTOR or eIF2a (Figure 4g,h ). Based on these data, the facilitating effects of GLP-1 (9-36) on late-phase LTP are unlikely to be associated with regulations on translation initiation via either mTORC1 or eIF2a signaling pathways.
| GLP-1 (9-36) administration in vivo leads to suppression of eEF2 phosphorylation
In addition to initiation, de novo protein synthesis is heavily regulated at the elongation phase through multiple translational elongation factors including eukaryotic elongation factor-2 (eEF2), which mediates peptidyl-tRNA translocation from the ribosomal A-site to P-site. Phosphorylation of eEF2 on Thr56 prevents it from binding to the ribosome, thus disrupting peptide growth and general protein synthesis (Kenney, Moore, Wang, & Proud, 2014) . Importantly, multiple lines of studies also point to a critical role of eEF2 phosphorylation in synaptic plasticity and memory formation (Taha, Gildish, Gal-Ben-Ari, & Rosenblum, 2013) . Therefore, we set out to determine the effects of GLP-1 (9-36) in vivo treatment on the state of eEF2 phosphorylation. Western blotting performed on hippocampi derived from GLP-1 (9-36)-treated mice revealed significantly decreased levels of phosphorylated (Thr56) eEF2 (Figure 5a ), which is associated with an increased capacity for general protein synthesis (Taha et al., 2013) . In contrast, acute in vitro treatment of hippocampal slices with GLP-1 (9-36) did not alter eEF2 phosphorylation ( Figure 5b ). Upstream regulators of eEF2 phosphorylation include mTORC1 and AMP-activated protein kinase (AMPK), a central molecular sensor functioning to maintain cellular energy homeostasis (Hardie, 2014; Horman et al., 2002) . As described above, GLP-1 (9-36)
does not affect mTORC1 signaling in our experiments (Figure 4a-e) .
We then examined the activity of AMPK by measuring levels of whether GLP-1 (9-36) functions through GLP-1R remains unclear (Ban et al., 2008; Nikolaidis et al., 2005; Poudyal, 2016; Robinson et al., 2016) . To further elucidate mechanisms associated with the LTPenhancing effects by GLP-1 (9-36), we co-administered (via i.p. injection) GLP-1 (9-36) with exendin (9-39) amide [EX(9-39)], the GLP-1R
antagonist (Green et al., 2005) . Compared to vehicle-treated control, EX(9-39) by itself inhibited LTP (Figure 6 ), which is consistent with previous studies demonstrating a critical role of GLP-1R in learning and memory (During et al., 2003) . Notably, the LTP enhancement induced by GLP-1 (9-36) was blunted entirely by EX(9-39) (Figure 6 ), indicating the involvement of GLP-1R in mediating the CNS effects of GLP-1 (9-36) under the current experimental paradigm.
| D I SCUSSION
In the current study, we have shown that GLP-1 (9-36), the main cleavage product of the gut hormone GLP-1, facilitates hippocampal LTP with chronic in vivo treatment in adult wild type mice. At the molecular level, GLP-1 (9-36) reduces protein levels of potassium channel Kv4.2 in the hippocampus, which is linked to elevated dendritic membrane excitability (Figure 3a ) (Chen et al., 2006) . Moreover, GLP-1 (9-36) treatment inhibits phosphorylation of the mRNA translational factor eEF2, which is associated with an increased capacity for de novo protein synthesis (Figure 5a ) (Taha et al., 2013) . These findings demonstrate that GLP-1 (9-36), the once-considered "bio-inactive" peptide, clearly exerts important physiological effects on neuronal plasticity in the hippocampus, a brain region critical for learning and memory.
FIG URE 4 GLP-1 (9-36) administration in vivo does not affect mTORC1 signaling cascade or eIF2a activity. Western blotting on hippocampal slices from mice treated with GLP-1 (9-36) (500 ng/g/day) displayed unaltered levels of (a) mTOR phosphorylation at Ser2448; (b) p70S6K phosphorylation at Thr389; (c) 4EBP1 phosphorylation at Thr37/46; (d) Akt phosphorylation at Thr473; (e) GSK3b phosphorylation at Ser9; and (f) eIF2a phosphorylation at Ser51. n 5 6 for GLP-1 (9-36)-treated group and n 5 4 for saline vehicle-treated group. Moreover, acute treatment of hippocampal slices with GLP-1 (9-36) did not alter phosphorylation levels of (g) mTOR or (h) eIF2a. n 5 4 DAY ET AL.
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FIG URE 5 GLP-1 (9-36) administration in vivo leads to suppression of eEF2 phosphorylation. (a) Western blotting on hippocampal slices from mice treated with GLP-1 (9-36) (500 ng/g/day) demonstrated significant reduced levels of eEF2 phosphorylation at Thr56; (b) acute treatment of hippocampal slices with GLP-1 (9-36) did not alter eEF2 phosphorylation; (c) phosphorylation of AMPKa was not affected by GLP-1 (9-36) in vivo treatment; (d) acute treatment of hippocampal slices with GLP-1 (9-36) led to increase of AMPKa phosphorylation; (e); levels of eEF1A was not changed by GLP-1 (9-36) treatment in vivo; (f) acute treatment of hippocampal slices with GLP-1 (9-36) did not alter eEF1A levels. n 5 6 for GLP-1 (9-36)-treated group and n 5 4 for saline vehicle-treated group. (g) SUnSET experiments on hippocampal slices from mice treated with GLP-1 (9-36) did not reveal any significant change of newly synthesized proteins assessed by puromycin incorporation. n 5 12 for GLP-1 (9-36) in vivo group and n 5 8 for saline vehicle-treated group and GLP-1 (9-36) in vitro group. *p < 0.05
Is there a link between regulation of Kv4.2 and eEF2 phosphorylation by GLP-1 (9-36)? Kv4.2 channels are expressed preferentially in hippocampal neurons and function as a key regulator for generation of backpropagating action potential (bAP), which is indispensable for LTP induction at the hippocampal Schaffer collateral pathway (as performed in the current study) under physiological conditions (Chen et al., 2006; Sheng, Tsaur, Jan, & Jan, 1992) . Previous studies have demonstrated that Kv4.2 knockout mice exhibit facilitation of hippocampal LTP induction (Chen et al., 2006) , and therefore a potential mechanism underlying the early LTP-enhancing effects by GLP-1 (9-36). On the other hand, multiple lines of studies show that up-regulation of signaling pathways controlling protein synthesis (e.g. mTORC1) is associated with enhancement of long-lasting synaptic plasticity (Hoeffer et al., 2008; Ma et al., 2011) . In agreement, GLP-1 (9-36) treatment results in an increased capacity for protein synthesis via inhibition of eEF2 phosphorylation, which could contribute to the enhancing effects of GLP-1 (9-36) on late-phase LTP. Nevertheless, the relationship between reduced Kv4.2 expression and decreased eEF2 phosphorylation associated with GLP-1 (9-36) treatment remains elusive. Typically
Kv4.2 inhibition leads to increased dendritic excitability, allowing more Ca 21 influx through voltage-gated calcium channels or NMDA receptors (Birnbaum et al., 2004; Cai et al., 2004; Ma et al., 2011) . It is generally considered that elevated Ca 21 (together with calmodulin) activates eEF2K (kinase for eEF2), leading to increased phosphorylation of eEF2 (Taha et al., 2013) , which is the opposite of our observation in that eEF2 phosphorylation is actually reduced by GLP-1 (9-36) ( Figure 5a ).
Of note, we also examined the effects of GLP-1 (9-36) on signaling pathway of mTORC1 and AMPK, two potential upstream regulators for eEF2 and its kinase eEF2K, but did not observe any significant alteration for either pathway. In the future, it would be interesting to elucidate the molecular mechanisms underlying eEF2 dephosphorylation effects by GLP-1 (9-36).
Long-lasting synaptic plasticity and memory is dependent on mRNA translation (Alberini, 2008; Costa-Mattioli, Sossin, Klann, & Sonenberg., 2009) . In contrast to the effects on the elongation phase of translation via inhibiting phosphorylation of eEF2, the current study did not reveal any effects of GLP-1 (9-36) on translation initiation, as indicated by lack of effects on activity of translation initiation factor eIF2 and mTORC1 signaling, which controls cap-dependent translation initiation (Klann, Antion, Banko, & Hou, 2004) . While much attention has been devoted to the initiation process for translational control, mounting evidence indicates that regulation at the elongation step is critical in modulation of protein synthesis in cellular environments such as neuronal dendrites where the translational capacity is low, thus both FIGU RE 6. initiation and elongation processes need to be upregulated to accomplish the substantial requirements of new protein synthesis associated with synaptic plasticity (Sutton & Schuman, 2006 It has been reported that acute application of GLP-1 (7-36), the precursor of GLP-1 (9-36), enhanced hippocampal LTP in rats (Gault & H€ olscher, 2008) . In contrast, we did not observe any effects on LTP when GLP-1 (9-36) was applied acutely on hippocampal slices, which is consistent with previous studies (Ma et al., 2012) . Such findings provide further support for the notion that GLP-1 (9-36) may execute its biological actions through molecular mechanisms distinct from GLP-1 (7-36). Meanwhile, our data from the EX(9-39) experiments indicates that the LTP-enhancing effects by GLP-1 (9-36) are dependent upon the GLP-1R, which mediate most, if not all of the biological effects of GLP-1 (7-36) (Campbell & Drucker, 2013; During et al., 2003) . Previous studies on non-neuronal systems have not determined whether GLP-1R is required for GLP-1(9-36) function (Ban et al., 2008 (Ban et al., , 2010 Poudyal, 2016) . While our data suggest involvement of GLP-1R in mediating the CNS effects of GLP-1 (9-36), future studies to elucidate detailed molecular mechanisms, including identification of potential alternative receptors, that mediate the physiological effects of GLP-1 (9-36) in brains are warranted.
In conclusion, the present study demonstrates enhancing effects of GLP-1 (9-36) on hippocampal synaptic plasticity, which could be attributed to its GLP-1R agonist effects, as well as regulation on dendritic membrane excitability and de novo protein synthesis. These findings are consistent with the idea that incretin hormones confer important effects on CNS, and contribute another piece of evidence to support the long-held theory of "brain-gut axis" (Latorre, Sternini, Giorgio, & Meerveld, 2016; Omran & Aziz, 2014) . The intrinsic instability (i.e. very short half-life), and its marked hypoglycemic activity (if given systematically) may present barriers for the use of GLP-1 (7-36) as a treatment option for cognitive dysfunction. As a result, mimics of GLP-1 (7-36) or DPP-4 inhibitors have been actively developed to improve its pharmacokinetics and are tested in neurodegenerative diseases (Aviles-Olmos et al., 2013 , 2014 Campbell & Drucker, 2013; Gejl et al., 2016; Sandoval & D'Alessio, 2015) . The natural cleavage product GLP-1 (9-36) is devoid of the aforementioned disadvantages of GLP-1 (7-36) and meanwhile possesses beneficial properties such as neuroprotection and scavenger of mitochondrial ROS. Future studies are needed to determine its potential as a novel, alternative therapeutic agent to target neuronal diseases with cognitive impairments.
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